AI-generated summary
The authors reviewed 10 adults with stable non-segmental vitiligo treated with upadacitinib at one hospital over one year. They report that 78.0% of lesions reached at least 25% repigmentation after 16 weeks, with higher response at 16 weeks than at 8 weeks, and acral lesions responding less well. The authors conclude the drug is safe and effective, but the study is small and uncontrolled.
- Participants
- 10
- Who or what was studied
- Adults with stable non-segmental vitiligo treated at Jingzhou Hospital of Yangtze University
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The study is a small, retrospective case series of 10 patients with no control group, and the abstract does not describe a formal safety analysis.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 308 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.